<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02627560</url>
  </required_header>
  <id_info>
    <org_study_id>2015/1722</org_study_id>
    <secondary_id>2015-003160-37</secondary_id>
    <nct_id>NCT02627560</nct_id>
  </id_info>
  <brief_title>The Effect of Topical Tranexamic Acid on Bleeding and Seroma Formation in After Undergoing Mastectomy</brief_title>
  <official_title>The Effect of Topical Administration of Tranexamic Acid on Postoperative Bleeding and Seroma Formation in Patients Undergoing Mastectomy: A Prospective Placebo-controlled Double Blinded Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alesund Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Olavs Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      After surgical procedures, interventions to reduce postoperative bleeding are of great
      importance. In this study, the effect will be investigated of smearing tranexamic acid, which
      is designed for injection, directly onto the raw wound surface (topical application) created
      during surgery. Topical application allows a small amount of drug to reach a large wound
      area, higher drug concentration in the exposed wound surface but very low concentration in
      the body, and no risk of injury from needles. The researchers have recently shown that
      topically applicated tranexamic acid reduces bleeding in women who had two-sided breast
      reduction surgery. Now it will be studied whether topically applicated tranexamic acid
      reduces bleeding after breast surgery for breast cancer.

      After surgery for breast cancer patients may also experience problems with long lasting
      seroma. Therefore it will at the same time be investigated whether topical tranexamic acid
      reduces the development of seroma in these patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Actual">October 1, 2018</completion_date>
  <primary_completion_date type="Actual">October 1, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>bleeding as defined by drain production per hour the first 24 hours</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>Drains are placed in surgical wounds during operation, and amount of blood on drains measured in ml</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Daily drain production up to drain removal - cumulative volume</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients having surgical bleeding in need of re-operation</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of postoperative aspirations of clinical seroma</measure>
    <time_frame>up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chronic seroma (lasting more than three months)</measure>
    <time_frame>3 months</time_frame>
    <description>volume of seroma aspirated</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">202</enrollment>
  <condition>Postoperative Hemorrhage</condition>
  <condition>Breast Neoplasms</condition>
  <condition>Seroma</condition>
  <arm_group>
    <arm_group_label>topical tranexamic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tranexamic acid to be smeared on surgical wounds before closure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>saline to be smeared on surgical wounds before closure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>moisten the surgical wound surface with 20 ml tranexamic acid 25 mg/ml</description>
    <arm_group_label>topical tranexamic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline</intervention_name>
    <description>moisten the surgical wound surface with 20 ml placebo (0.9% saline)</description>
    <arm_group_label>placebo control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  breast cancer

          -  undergoing unilateral mastectomy with or without axillary node dissection

          -  received adequate oral and written information about the study and signed an
             informed-consent form

        Exclusion Criteria:

          -  pregnant or breastfeeding

          -  known thromboembolic disease or with high risk of thromboembolism, warranting extra
             anticoagulation in connection with the procedure

          -  known allergy to tranexamic acid/Cyklokapron®
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Petter Aadahl, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>St. Olavs Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sverrir Olafsson</last_name>
    <role>Study Director</role>
    <affiliation>Ålesund Sykehus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Olavs University Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Surgery, Aalesund Hospital</name>
      <address>
        <city>Ålesund</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <link>
    <url>https://bjssjournals.onlinelibrary.wiley.com/doi/full/10.1002/bjs5.50248?af=R</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Ausen K, Fossmark R, Spigset O, Pleym H. Randomized clinical trial of topical tranexamic acid after reduction mammoplasty. Br J Surg. 2015 Oct;102(11):1348-53. doi: 10.1002/bjs.9878.</citation>
    <PMID>26349843</PMID>
  </reference>
  <results_reference>
    <citation>Ausen K, Hagen AI, Østbyhaug HS, Olafsson S, Kvalsund BJ, Spigset O, Pleym H. Topical moistening of mastectomy wounds with diluted tranexamic acid to reduce bleeding: randomized clinical trial. BJS Open. 2020 Apr;4(2):216-224. doi: 10.1002/bjs5.50248. Epub 2019 Dec 26.</citation>
    <PMID>32207575</PMID>
  </results_reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>December 2, 2015</study_first_submitted>
  <study_first_submitted_qc>December 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2015</study_first_posted>
  <last_update_submitted>May 8, 2020</last_update_submitted>
  <last_update_submitted_qc>May 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Administration, topical</keyword>
  <keyword>Tranexamic acid</keyword>
  <keyword>Postoperative care</keyword>
  <keyword>Mastectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Seroma</mesh_term>
    <mesh_term>Postoperative Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

